228 related articles for article (PubMed ID: 36723899)
1. 68Ga-PSMA and 68Ga-FAPI-04 PET/CT Findings With 18F-FDG PET/CT in a Patient With Recurrent Prostate Cancer.
Tatar G; Ergül N; Baloğlu MC; Arslan E; Çermik TF
Clin Nucl Med; 2023 Mar; 48(3):e135-e137. PubMed ID: 36723899
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET/CT in the Evaluation of Adenoid Cystic Carcinoma-A Prospective Study.
Shamim SA; Kumar N; Arora G; Kumar D; Pathak A; Thakkar A; Sikka K; Singh CA; Kakkar A; Bhalla AS
Clin Nucl Med; 2023 Nov; 48(11):e509-e515. PubMed ID: 37812520
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach.
Miceli A; Riondato M; D'Amico F; Donegani MI; Piol N; Mora M; Spina B; Morbelli S; Bauckneht M
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577898
[TBL] [Abstract][Full Text] [Related]
6. 68 Ga-FAPI PET/CT Detected Non-PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer.
Pang Y; Meng T; Xu W; Shang Q; Chen H
Clin Nucl Med; 2022 Dec; 47(12):1108-1111. PubMed ID: 35961368
[TBL] [Abstract][Full Text] [Related]
7. Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 Vaccination.
Ah-Thiane L; Ferrer L; Maucherat B; Fleury V; Le Thiec M; Rusu D; Rousseau C
Clin Nucl Med; 2022 Jul; 47(7):575-582. PubMed ID: 35675134
[TBL] [Abstract][Full Text] [Related]
8. A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa.
Lawal IO; Adediran OA; Muzahir S; Friend S; Bhave MA; Meisel J; Torres MA; Styblo TM; Graham C; Holbrook A; Kalinsky K; Fielder B; Crowe RJ; Ulaner GA; Schuster DM
Clin Nucl Med; 2023 Jan; 48(1):e26-e27. PubMed ID: 36469077
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT.
Isik EG; Has-Simsek D; Sanli O; Sanli Y; Kuyumcu S
Clin Nucl Med; 2022 Jan; 47(1):e54-e55. PubMed ID: 34392294
[TBL] [Abstract][Full Text] [Related]
10. Visualization of Intermetastatic Heterogeneity in Mixed Neuroendocrine Carcinoma-Acinar Adenocarcinoma of the Prostate by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET/CT.
Cai J; Xu W; Meng T; Pang Y; Chen H
Clin Nucl Med; 2023 Aug; 48(8):743-745. PubMed ID: 37220226
[TBL] [Abstract][Full Text] [Related]
11. Is 68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma?
Can C; Gündoğan C; Kömek H
Clin Nucl Med; 2021 Apr; 46(4):e233-e235. PubMed ID: 33031232
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Poorly Differentiated Thyroid Cancer With Heterogeneous Distribution of 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA on PET/CT.
Civan C; Isik EG; Simsek DH
Clin Nucl Med; 2021 Apr; 46(4):e212-e213. PubMed ID: 33156050
[TBL] [Abstract][Full Text] [Related]
13. PET/CT With 68Ga-PSMA and 18F-FDG in Metastatic Adenoid Cystic Carcinoma: Report of 2 Cases.
Isgoren S; Hekimsoy T; Koroglu E; Demir H
Clin Nucl Med; 2022 May; 47(5):e423-e424. PubMed ID: 35234196
[TBL] [Abstract][Full Text] [Related]
14. Urinary Reflux Into the Prostate Gland and Seminal Vesicles: A Potential Pitfall in 18F-FDG and 68Ga-PSMA PET/CT.
Hekimsoy T; Gorur GD; Isgoren S; Uslu H; Demir H
Clin Nucl Med; 2020 Jul; 45(7):536-537. PubMed ID: 32433177
[TBL] [Abstract][Full Text] [Related]
15. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi Sarcoma.
Tatar G; Beyhan E; Erol Fenercioğlu Ö; Arslan E; Çermik TF
Clin Nucl Med; 2022 Sep; 47(9):e596-e599. PubMed ID: 35930714
[TBL] [Abstract][Full Text] [Related]
17. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
18. The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.
Shu Q; Deng M; Hu M; Liu M; Chen X; Chen Y; Cai L
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1442-1452. PubMed ID: 36609606
[TBL] [Abstract][Full Text] [Related]
19. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
